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Abstract: 
Silymarin, an extract from milk thistle (Silybum marianum), and its purified flavonolignans have 
been recently shown to inhibit hepatitis C virus (HCV) infection, both in vitro and in vivo. In the 
current study, we further characterized silymarin's antiviral actions. Silymarin had antiviral 
effects against hepatitis C virus cell culture (HCVcc) infection that included inhibition of virus 
entry, RNA and protein expression, and infectious virus production. Silymarin did not block 
HCVcc binding to cells but inhibited the entry of several viral pseudoparticles (pp), and fusion of 
HCVpp with liposomes. Silymarin but not silibinin inhibited genotype 2a NS5B RNA-dependent 
RNA polymerase (RdRp) activity at concentrations 5 to 10 times higher than required for anti-
HCVcc effects. Furthermore, silymarin had inefficient activity on the genotype 1b BK and four 
1b RDRPs derived from HCV-infected patients. Moreover, silymarin did not inhibit HCV 
replication in five independent genotype 1a, 1b, and 2a replicon cell lines that did not produce 
infectious virus. Silymarin inhibited microsomal triglyceride transfer protein activity, 
apolipoprotein B secretion, and infectious virion production into culture supernatants. Silymarin 
also blocked cell-to-cell spread of virus. Conclusion: Although inhibition of in vitro NS5B 
polymerase activity is demonstrable, the mechanisms of silymarin's antiviral action appear to 
include blocking of virus entry and transmission, possibly by targeting the host cell.  
 
Article: 
Chronic hepatitis C is a serious global medical problem necessitating novel, effective, 
inexpensive, and less toxic treatments. Hepatitis C virus (HCV) infects an estimated 130 million 
people throughout the world, leading to a half million deaths per year due to liver disease.1 
 
Pegylated interferon (IFN) plus ribavirin therapy is the current treatment for the patient with 
chronic hepatitis C.2 However, 50% of treated patients do not clear viremia during treatment, 
which is costly and has significant side effects. As a result, many patients use natural products to 
supplement or circumvent IFN-based regimens, with silymarin being the most common botanical 
medicine.3 
 
Silymarin is an extract from the plant Silybum marianum, which consists of at least seven 
flavonolignans and the flavonoid taxifolin.4 Silibinin is a partially purified mixture of two 
flavonolignans, silybin A and silybin B. Silymarin has been used to treat a range of liver 
disorders, including hepatitis, cirrhosis, and poisoning from wild mushrooms.5 Recently, we 
showed silymarin inhibits HCV infection of Huh7 and Huh7.5.1 cells,6 and Ferenci's group 
showed that intravenous silibinin administration reduces viral loads in previous nonresponders to 
IFN therapy.7 Therefore, in the current study, we determined the stages in the HCV life cycle 
that are blocked by silymarin. 
 
MATERIALS AND METHODS 
Reagents 
Human hepatoma Huh7 cells were grown in Huh7 medium as described.6 HepG2 cells and 
Huh7.5.1 cells8 were cultured in Huh7 medium. Blazing Blight 7 (BB7) and Full Length-NEO 
(FL-NEO) cells are Huh7 cell lines that contain subgenomic and genomic length genotype 1b 
replicons, respectively.9 JFH-1 subgenomic genotype 2a replicon cell lines in Huh7 or Huh7.5 
backgrounds were generated by transfecting in vitro transcribed subgenomic replicon (SGR) 
SGR-JFH1 replicon RNA into Huh7 or Huh7.5 and selecting with 800 μg/mL G418. Single 
colonies expressing the highest level of HCV protein were designated SGR7 and SGR7.5. Luc-
ubi-neo/ET is a subgenomic genotype 1b-derived replicon cell line.10 The HCV genotype 1a 
H77s subgenomic replicon cell line has been described previously.11 All replicon lines were 
maintained in Huh7 medium containing 400 μg/mL G418. Primary human hepatocytes were 
provided by Dr. Stephen Strom, University of Pittsburgh, and maintained in hepatocyte culture 
medium (Lonza, Walkersville, MD). 
 
JFH-1 viral stock preparation, cell infection, and titration was performed as described.6 
Silymarin from US Pharmacopeia (Rockville, MD) was used in all experiments except for the 
microsomal triglyceride transfer protein (MTP) (Fig. 4A) and apolipoprotein B (apoB) (Fig. 4E) 
assays, where silymarin from Sigma was used. Sigma silymarin contains similar levels of the 
major flavonolignans to USP silymarin, as described by Wen et al.12 Stocks were prepared in 
dimethylsulfoxide (DMSO) at a concentration of 50 mg/mL. Silibinin was purified from 
silymarin as described.13 
 
Egg yolk phosphatidylcholine, cholesterol, and Triton X-100 were purchased from Sigma. 
Octadecyl rhodamine B chloride (R18) was from Fluoprobes. 
 
Addition of Compounds to Cultures 
Silymarin was further diluted in DMSO before use, and the final concentration of DMSO in 
culture media was always less than 0.5%. Silymarin treatment involved exposing cells to a single 
administration of silymarin for various times. DMSO was included as a solvent control. To focus 
on the effects of silymarin on infectious virus production, in some experiments cells were first 
infected at a multiplicity of infection (MOI) of 0.01, and cells were passaged at 72 hours after 
infection, followed by addition of silymarin 24 hours after passaging, or 96 hours after infection. 
Under these conditions, the culture was fully infected (Supporting Fig. S1). 
 
Roferon, Intron-A, or Pegasys was used as a positive control for antiviral effects. Roferon 
(Roche, Palo Alto, CA) was used at 100 IU/mL, Pegasys was used at 10 ng/mL, and Intron-A 
was used at various concentrations. BMS-200150, a small molecule inhibitor of MTP, was 
provided by Pablo Gastaminza and Francis Chisari. 
 
Western Blot Analysis 
Western blots were performed as described.6 Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), apoB, Stat1, NS5A in FL-NEO and BB7 cells, and core proteins were detected using 
commercial antiserum (Santa Cruz Biotechnology, Santa Cruz, CA; BioDesign/Meridian Life 
Science, Saco, ME; Affinity BioReagents, Golden, CO). NS5A in JFH-1-infected cells was 
detected with serum from patients infected with HCV genotype 2a. 
 
HCV RNA Quantitation 
HCV RNA was quantitated by real time reverse transcription polymerase chain reaction, as 
previously described.14 
 
HCV Luciferase Replicon Assay 
Luc-ubi-neo cells were plated and grown for 24 hours. Medium was removed, and the cells 
washed once and treated subsequently with given concentrations of silymarin or DMSO in 
triplicate. After 3 days of incubation at 37°C, cell culture medium was removed and cells were 
lysed by freeze-thawing in buffer and luciferase assays were performed. 
 
HCV-1a Replicon Assay 
Antiviral studies to determine the impact of silymarin treatment on HCV RNA levels with the 
genotype 1a replicon were conducted using real time reverse transcription polymerase chain 
reaction and assay conditions previously described.15 
 
HCV NS5B Polymerase Assays 
NS5BΔC21 C-terminally fused to a hexa-histidine tag was expressed and purified for HCV JFH1 
and for the genotype 1b isolates as described.16, 17 All measurements were done in triplicate, and 
the half maximal inhibitory concentration (IC50) values were calculated with GraphPad Prism. 
 
Viral Pseudoparticle Entry Assays 
Pseudoviruses were generated as previously described.18 Huh-7.5 cells were pretreated for 1 hour 
with 40, 80, and 160 μM silymarin (SM) or equivalent volume of DMSO, diluted in media. Cells 
were inoculated with an equal volume of pseudoparticles, bringing the final concentration of SM 
to 20, 40, and 80 μM. Seventy-two hours postinfection, the medium was removed and cells lysed 
with cell lysis buffer (Promega, Madison, WI). Luciferase activity was then measured. Specific 
infectivity was calculated by subtracting the mean Env-pp signal from the HCVpp, Murine 
Leukemia Virus pseudoparticle (MLVpp), or Vesicular Stomatitis Virus pseudoparticle (VSVpp) 
signals. Relative infectivity was then calculated as a percentage of untreated control cell 
infection; in other words, the mean luciferase value of the replicate untreated cells was defined as 
100%. 
 
Fusion Assay 
Fusion between HCVpp and liposomes was assayed as already described.19 Briefly, liposomes 
composed of phosphatidylcholine, cholesterol, and octadecyl rhodamine B chloride (R18) 
(65:30:5 mol%) were added at a 15-μM final concentration to a cuvette at 37°C containing 
HCVpp in phosphate-buffered saline at pH 7.2. After equilibration, diluted HCl was added to pH 
5.0 final and lipid mixing measured as the dequenching of R18 (excitation 560 nm, emission 590 
nm), resulting in an increase in the fluorescence signal. Silymarin was preincubated with HCVpp 
and liposomes for 3 minutes at 37°C, and lipid mixing measured after medium acidification. 
 
Infectious Virion Production 
Culture supernatants were harvested at defined time points postinfection, and supernatants were 
clarified by centrifugation. Intracellular virus titers were determined after treatment with 
Brefeldin A, which has been shown to block HCV release by causing intracellular accumulation 
of virions. For this, treated cells were scraped into phosphate-buffered saline and lysed by freeze-
thawing as described.20 All supernatants were stored at −80°C before dilution and titering on 
naïve Huh7.5.1 cells using standard focus-forming unit assays as previously described.8 
 
Cell-to-Cell Spread 
Cell-to-cell spread of virus was measured as previously described.21 Briefly, unlabeled naïve 
“target” cells were incubated with HCV H77/JFH infected “producer” cells that were labeled 
with 5-chloromethylfluorescein diacetate (Molecular Probes, Invitrogen, Carlsbad, CA). A 
neutralizing antibody was added to the co-culture to abrogate the infectivity and transmission of 
cell-free virus particles within the culture media, allowing us to quantify antibody insensitive 
viral transmission. Infection was quantified by staining the co-cultures with an anti-NS5A 
antibody (9E10) and appropriate secondary antibody, followed by flow cytometry. 
 
apoB Enzyme-Linked Immunosorbent Assay 
Huh7.5.1 cells were grown overnight in Huh7 media. The media was removed, cells were 
washed, and fresh medium with the appropriate compounds was added to cells. Culture 
supernatants were harvested at 24 and 48 hours later, clarified by centrifugation, and stored at 
−80°C. Apolipoprotein B was measured by enzyme-linked immunosorbent assay (ELISA) using 
manufacturer's protocol (ALerCHEK, Portland, ME). 
 
MTP Assay 
MTP activity was measured using a commercially available fluorescence assay using a 
commercial kit (Roar Biomedical Inc., New York, NY) as described.22 
 
Statistics 
Differences between means of readings were compared using a Student t test. A P-value of <0.05 
was considered significant. 
 
RESULTS 
We previously showed that silymarin inhibits HCV RNA and protein expression in the HCVcc 
system with JFH-1 virus.6 Figure 1A demonstrates that, in addition to wild-type JFH-1 virus, 
silymarin also blocks replication of HCVcc chimeras, including constructs that contain the H77 
(genotype 1a) and J6 (genotype 2a) structural genes in the JFH-1 nonstructural gene backbone. 
Inhibition of HCVcc was 50% for H77/JFH and 75% for J6/JFH chimeras. Thus, silymarin has 
antiviral actions against multiple HCVcc infectious systems. To determine whether silymarin 
could inhibit binding of HCV virions to cells, we performed virus-cell binding studies at 4°C 
under conditions in which virus binds to but does not enter cells.23 As shown in Fig. 1B, when 
silymarin was present only during virus-binding, there was little effect on HCV replication. 
However, if silymarin was added to cells immediately after binding and for the duration of the 
infection, HCV protein expression was severely impaired. The same effect was observed if 
silymarin was present during binding and for the duration of the experiment. Next, to determine 
whether silymarin blocked virus entry, we tested the effect of silymarin on viral pseudoparticle 
entry including HCVpp, VSVpp, and MLVpp. Figure 1C demonstrates that silymarin inhibited 
the entry of all three pseudotyped viruses. We then examined the effect of silymarin on the 
fusion of HCVpp with fluorescent liposomes, which examines the effects of compounds on lipid 
mixing and membrane fusion.24 As shown in Fig. 1D, silymarin drastically inhibited HCVpp-
mediated fusion by 80% at 10 μM silymarin, whereas 20 μM led to a 90% reduction in fusion. 
DMSO, the solvent control, did not affect fusion. The IC50 of silymarin for membrane fusion 
inhibition was estimated at 5 μM, far below the doses of silymarin known to confer cytotoxicity 
in Huh7.5.1 cells (>80 μM, Supporting Fig. S2, Panel E). The data suggest that silymarin does 
not affect binding but inhibits the entry of HCV at the fusion stage. 
 
 
 
Figure 1: Antiviral effects of silymarin against HCVcc. (A) Silymarin inhibits virus infection in multiple HCVcc 
systems. Huh-7.5 cells were incubated with 80 μM silymarin or DMSO for 1 hour at 37°C before inoculation with 
either H77/JFH or J6/JFH HCVcc viruses. The infection was allowed to proceed in the presence of the compounds 
for 48 and 72 hours before virus was quantitated by staining for NS5A-positive foci. Percent inhibition reflects 
inhibition of NS5A-positive foci by silymarin relative to the DMSO control. (B) Silymarin does not block virus 
binding. Huh7.5.1 cells were incubated at 4°C for 5 hours in the presence of HCVcc (JFH-1, MOI of 0.01) with or 
without 40 μM silymarin. Cells were then washed extensively at 4°C and then cells were incubated for 72 hours at 
37°C to allow the HCV lifecycle to continue in the presence or absence of additional silymarin. “M” denotes mock 
infected cells. “0” denotes cells that were infected but not treated with anything. “Binding @ 4C” denotes silymarin 
was only present during the 5-hour adsorption period. “Post-binding” denotes that silymarin was added after the 5-
hour adsorption period and for the duration of the infection. “Normal” denotes that silymarin was present during the 
5-hour adsorption and for the duration of the infection. (C) Silymarin inhibits pseudoparticle entry. Huh-7.5 cells 
were treated with silymarin (SM) or an equivalent volume of DMSO for 1 hour before infection with HCV, VSV, or 
MLV pseudoparticles (pp). Seventy-two hours postinfection, the medium was removed and luciferase activity was 
measured on cell lysates. (D) Silymarin blocks HCVpp-mediated lipid mixing. HCVpp in phosphate-buffered saline 
at pH 7.2 were incubated or not with indicated concentrations of silymarin in DMSO, for 3 minutes at 37°C, in the 
presence of phosphatidylcholine:cholesterol:R18 liposomes. Acidification to pH 5.0 was performed by adding 
diluted HCl to the cuvette, and R18 dequenching was assayed for 15 minutes at excitation and emission wavelengths 
of 560 and 590 nm, respectively. Maximal dequenching was obtained after addition of 0.1% final Triton X-100 to 
the cuvette. Black, no silymarin; blue, 10 μM; green, 20 μM; and red, 80 μM; silymarin, respectively. Dotted curve, 
lipid mixing in the presence of 1% final DMSO (highest concentration used in the assay). (E) Silymarin inhibits 
HCV RNA production. Huh7.5.1 cells were infected at an MOI of 0.01 with JFH-1, and 24 hours later, silymarin (40 
μM) or IFN (10 units/mL) was added to cells, and thereafter, total RNA was isolated from cells at the indicated time 
points. HCV RNA was quantitated by real-time reverse transcription polymerase chain reaction. Asterisks indicate 
that silymarin or IFN reduction of viral loads is significantly different from untreated cells (P < 0.01). (F) Silymarin 
reduces infectious virus production into culture supernatants. Huh7.5.1 cells were infected at an MOI of 0.01 with 
JFH-1 in the presence of 40 μM silymarin or DMSO, and supernatants were harvested 48 and 72 hours postinfection 
and titered by focus-forming unit assay on naïve Huh7.5.1 cells. 
 
Next, we examined the kinetics of inhibition of HCV RNA production. In this experiment, we 
first infected cells for 24 hours, followed by silymarin administration, or IFN-α as a positive 
control. As shown in Fig. 1E, relative to untreated cells, silymarin caused a significant (P < 0.01) 
reduction in JFH-1 RNA production at 48 and 72 hours after treatment. IFN treatment also 
reduced viral loads. However, significant suppression (P < 0.01) of HCV RNA production by 
IFN started at 18 hours posttreatment and was maintained until 72 hours of treatment. Thus, the 
kinetics of silymarin mediated suppression of HCV RNA replication were delayed as compared 
with IFN. 
 
As shown in Fig. 1F, silymarin reduced infectious virus yields (measured as focus/mL) by 
fivefold and twofold at 48 and 72 hours postinfection from Huh7.5.1 cells (and in Huh7 cells; 
data not shown). We can rule out the possibility of carryover silymarin from the initial culture 
because the supernatants were diluted 1:5 to 1:1000 before testing on naïve cells. Altogether, the 
data show that silymarin does not affect virus binding to cells but inhibits virus entry and fusion, 
HCV protein and RNA synthesis, and production of progeny viruses in culture supernatants. 
 
Inhibition of HCV RNA and protein expression by silymarin could be attributable to direct 
inhibition of viral enzymes, as recently shown for NS5B polymerase activity.25 Therefore, we 
tested whether silymarin and silibinin block HCV NS5B polymerase activity. Recombinant 
NS5B protein from JFH-1 (genotype 2a) lacking the C-terminal 21 amino acids was expressed in 
Escherichia coli and purified.16 As shown in Fig. 2, silymarin was able to inhibit JFH-1 NS5B 
polymerase activity, with an IC50 for silymarin at approximately 300 μM. Silibinin had minimal 
effects on JFH-1 polymerase, but only at very high doses (IC50 > 400 μM), which were at least 
fivefold to 10-fold higher than effective antiviral doses in vitro.6 At the doses required for 
inhibition of in vitro NS5B polymerase activity, silymarin used in this study was toxic to 
cultured Huh76 and Huh7.5.1 cells (Supporting Fig. S2). 
 
 
 
Figure 2: Silymarin inhibits JFH-1 polymerase at high dose. HCV NS5B polymerase from isolate JFH-1 (genotype 
2a) was incubated with the indicated concentrations of silymarin or silibinin, respectively, in the presence of 
α[32P]GTP and polyC. Incorporation of radioactivity was quantified by trichloroacetic acid precipitation and liquid 
scintillation counting. Silymarin and to a lesser degree, silibinin, inhibited JFH-1 polymerase. 
 
We next tested silymarin on RNA-dependent RNA polymerase (RdRp) activity of the genotype 
1b BK strain and four patient-derived 1b RdRps from patients in the Virahep-C clinical study.26 
The RNA polymerase activities of the patient-derived enzymes were variable (16%-104% 
relative to the well-characterized BK enzyme; Table 1). Silymarin inhibited all five RdRps, with 
IC50 values ranging from 27.7 to 162 μM. However, in four of the five cases, the inhibitory 
activity of silymarin rapidly plateaued, with maximal inhibition levels of 42.6% to 82.8% 
relative to the activity in the absence of silymarin (Supporting Fig. S3). The fifth enzyme (#242) 
had an inhibition profile that could not be fit to a single-phase exponential decay curve, but its 
maximal inhibition by silymarin was only 43% and its apparent IC50 was greater than 1000 μM. 
Therefore, the IC50 values for most of these subtype 1b RdRps were respectable below the 
plateau level, but the enzymes were poorly inhibited by silymarin at the concentrations employed 
in the cell culture experiments. 
 
Table 1: Inhibition Profiles of Genotype 1b RdRps by Silymarin 
Polymerase Function 
Polymerase 
BK #234 #242 #245 #103 
 Relative RdRp activity 100 15.8 104 99 38.3 
IC50 (μM) 27.7 45.4 >1000 162 162 
Maximal inhibition (%) 48.5 42.6 43.0 53.3 82.8 
Polymerase assays were performed and analyzed as described in Materials and Methods. IC50, half-maximal inhibitory concentration. 
 
If silymarin truly inhibits NS5B polymerase activity, it should be able to inhibit HCV replication 
in replicon cell lines that do not produce infectious virus. Figure 3A-C depicts the effects of 
various doses of silymarin on HCV protein and RNA expression in genotype 1b BB7 
subgenomic and FL-NEO genomic replicon cell lines. Silymarin did not significantly inhibit 
viral protein expression in either cell line when assessed by western blot (Fig. 3A) or by 
immunofluorescence (Fig. 3B). Silymarin did not inhibit HCV RNA expression in either cell line 
(Fig. 3C). HCV replication was also not inhibited by silymarin in Luc-ubi-neo/ET cells, an 
independent genotype 1b replicon (Fig. 3D), or in a subgenomic genotype 1a replicon cell line 
(Fig. 3E). In contrast, treatment with IFN-α caused robust suppression of HCV RNA production 
from the HCV-1a replicon. We tested concentrations of silymarin up to 1000 μM but failed to 
see any suppression of HCV RNA from the 1a replicon that was independent of cytotoxicity, 
measured as GAPDH messenger RNA levels (Supporting Fig. S4). NS5A protein expression was 
not affected by silymarin in JFH-1-derived genotype 2a SGR7 (Fig. 3F) or SGR7.5 replicon cell 
lines (data not shown). Furthermore, extended treatment of FL-NEO replicon cells (or BB7 cells; 
data not shown) for 13 days did not affect the levels of HCV NS5A protein (Supporting Fig. S5). 
Therefore, silymarin had no antiviral activity against replicon cell lines that did not produce 
infectious virus. The data in Figs. 2 and 3 suggest that silymarin inhibition of NS5B polymerase 
activity is not a significant component of silymarin's anti-HCV activity in the HCVcc system. 
 
 
Figure 3: Silymarin does not block HCV replication in HCV replicon cell lines. Cells were treated with the 
indicated doses of silymarin and incubated for 72 hours before replication was assessed. (A) Protein expression in 
subgenomic BB7 and genomic FL-NEO HCV-1b replicons after treatment with 20 to 80 μM of silymarin. D, 
DMSO. Positions of HCV NS5A and cellular Stat1 proteins are indicated. (B) Intracellular NS5A protein expression 
in DMSO and silymarin treated FL-NEO cells. Cells were treated as described previously, and NS5A protein 
detected by immunofluorescence as described in the Materials and Methods. NS5A-positive cells are depicted in 
green, and the blue cells represent nuclei counterstained by 4',6-diamidino-2-phenylindole. (C) HCV RNA levels in 
FL-NEO and BB7 cells. (D) Effect of silymarin against Luc-ubi-neo/ET cells, a Con1-based genotype 1b replicon 
subgenomic replicon. Values represent percent change in luciferase light units relative to DMSO control. (E) Effect 
on HCV-1a subgenomic replicon. Left panel shows HCV and GAPDH RNA levels after silymarin treatment, 
whereas the right panel shows RNA levels after treatment with Intron-A (recombinant IFN-α). (F) Effect of 
silymarin on subgenomic genotype 2a JFH-1-derived Huh7 replicon cell line. Cells were treated with 20 or 40 μM 
silymarin once or each day for 3 days. Positions of HCV NS5A and cellular GAPDH proteins are indicated. 
 
HCV assembles at lipid droplets,27, 28 and the virus is thought to exit the infected liver cell by 
hitching a ride on the apolipoprotein assembly and secretion pathway, in particular MTP-
dependent very-low-density lipoprotein release.20, 29, 30 Because silymarin blocked infectious 
virus production (Fig. 1), we determined whether silymarin also inhibits MTP activity and apoB 
secretion. In these studies, silymarin was added to cells that were either fully infected (96 hours 
postinfection) or chronically infected for 14 days. Thus, the experimental design effectively 
eliminated antiviral effects involving blockade of virus entry and instead allowed us to focus on 
the effects of silymarin on production of progeny viruses. Silymarin inhibited MTP activity in a 
dose-dependent manner in 14-day chronically infected cells by 25% ± 15% and in noninfected 
cells by 66% ± 1% at 80 μM (Fig. 4A). Naringenin, shown recently to block MTP-dependent 
virus release,22 also blocked MTP activity. Silymarin inhibition of MTP activity correlated with 
reduced apoB secretion in both mock and JFH-1-infected Huh7.5.1 cells (Fig. 4B). The small 
molecule inhibitor of MTP, BMS-200150, served as a positive control for inhibition of apoB 
secretion. Silymarin inhibition of MTP activity and apoB secretion correlated with a reduction in 
de novo virion production from fully infected cultures treated for 5 hours (Fig. 4C). Importantly, 
the reduction in infectious virus production was not attributable to a reduction in intracellular 
replication, because NS5A protein levels were not affected by the 5-hour treatments with 
DMSO, silymarin, or BMS-200150 (Fig. 4D). Furthermore, the effect on apoB secretion was not 
unique to Huh7 cells, because silymarin also caused dose-dependent suppression of apoB 
secretion from primary human hepatocytes (Fig. 4E) and HepG2 cells, as measured by ELISA 
and western blot (Fig. 4F). When we examined intracellular infectious virus as a measure of 
virus assembly, the general secretion inhibitor Brefeldin A caused accumulation of intracellular 
infectious virus, which was inhibited by the MTP inhibitor BMS-200150, as described by 
Gastaminza et al.20 However, silymarin had no effect on Brefeldin A-induced accumulation of 
infectious virus (Supporting Fig. S6). Collectively, the data demonstrate that silymarin blocks 
MTP-dependent apoB secretion and infectious virion production into culture supernatants, but 
does not appear to block virus assembly. We then determined whether silymarin blocks other 
pathways of virus transmission. 
 
 
Figure 4: Silymarin inhibits microsomal triglyceride transfer protein (MTP) activity, apolipoprotein B (apoB) 
secretion, and infectious virus production. (A) Silymarin inhibits MTP activity in Huh7.5.1 cells. Chronically 
infected Huh7.5.1 cells (14 days postinfection), and uninfected cells were treated with the indicated micromolar 
doses of silymarin (SM) or as a positive control, 200 μg/mL naringenin (NN), and 24 hours later MTP activity was 
measured as described in Materials and Methods. (B) Silymarin inhibits apoB secretion from mock and HCV-
infected cells. Huh7.5.1 cells were infected or mock-infected with JFH-1 at an MOI of 0.01 for 96 hours before 
treatment with fresh medium containing DMSO, 10 μM BMS-200150 (a small molecule inhibitor of MTP), or 
silymarin at the indicated micromolar doses for 5 hours. Culture supernatants were harvested and apoB measured by 
ELISA. (C) De novo infectious virion production into culture supernatants is blocked by silymarin. Supernatants 
from panel B were diluted 1:20, and infectious titers were determined by focus-forming unit assay on naïve 
Huh7.5.1 cells. (D) Treatment of infected cells for 5 hours does not inhibit intracellular HCV replication. Protein 
lysates were harvested from cultures described in panel B, and equal amounts of total protein were blotted for 
NS5A. The positions of HCV NS5A and loading control GAPDH are indicated. D is the DMSO control, 40, 80, and 
120 are the doses of silymarin in μM. (E) Silymarin blocks apoB secretion from primary human hepatocytes. Cells 
were treated with the indicated concentrations of SM for 24 hours before supernatants were harvested, and apoB was 
measured by ELISA. (F) Silymarin blocks apoB secretion in HepG2 cells. Cells were treated with the indicated 
micromolar concentrations of silymarin for 5 hours before supernatants were harvested and apoB measured by 
ELISA. Inset, Silymarin blocks intracellular apoB levels. Cell lysates from HepG2 cells treated in panel F were 
probed for apoB by western blot. ApoB100 and loading control GAPDH are indicated with arrows. M is the media 
control, D is the DMSO control. 
 
It has been recently shown that, in addition to releasing virus particles into culture medium, HCV 
is capable of direct cell-to-cell transmission.21 To examine effects of silymarin on this antibody-
insensitive route of transmission, we used a novel assay in which fluorescently labeled infected 
producer cells were mixed with unlabeled naïve cells, and HCV NS5A protein expression was 
detected using antibodies labeled in the red spectrum. Silymarin reduced both total and cell-to-
cell transmission (Fig. 5A). We also observed equal suppression of both total and cell-to-cell 
transmission (Fig. 5B), suggesting that silymarin does not discriminate between routes of virus 
transmission. 
 
 
Figure 5: Silymarin inhibits total virus transmission and cell-to-cell spread. Naïve unlabeled Huh-7.5 cell targets 
were preincubated with 80 μM silymarin or equivalent volume of DMSO for 1 hour at 37°C. The pretreated cells 
were then co-cultured with 5-chloromethylfluorescein diacetate-labeled H77/JFH-infected Huh-7.5 producers for 48 
hours. The cultures were performed in the presence of either monoclonal antibody 9/27, an anti-E2 (HVR) 
neutralizing antibody, or an anti-HIV gp120 irrelevant control, monoclonal antibody 10/76B. Each treatment was 
performed in duplicate. The co-cultures were harvested, stained, and analyzed by flow cytometry, and the 
percentage of infected cells was calculated. Cell culture media from each co-culture was tested for the presence of 
HCVcc particles. Released H77/JFH virus were readily detectable in media containing control antibody, and no 
infectious particles were detected in the media containing monoclonal antibody 9/27, indicating that extracellular 
spread of virus was not occurring, and only cell-cell spread was operative. (A) Silymarin (SM) reduces both total 
and cell:cell transmission. (B) Silymarin inhibits both total and cell:cell transmission in comparable manner, 
suggesting that it does not discriminate between the alternative routes. 
 
 
 
DISCUSSION 
Despite global use for millenia, the detailed molecular mechanisms of silymarin-induced 
hepatoprotection are not known. In recent studies,6, 31 we have shown that silymarin displays 
antiviral, anti-inflammatory, and immunomodulatory functions. These activities, together with 
antioxidant functions of silymarin,32 could effectively constitute the hepatoprotection observed in 
many animal models of liver disease.33-35 Using HCVpp, HCVcc, and liposome mixing 
experiments, we demonstrate that silymarin inhibits virus entry and fusion, RNA and protein 
synthesis, and infectious virus production into culture supernatants and cell-to-cell spread. 
Silymarin but not silibinin inhibited NS5B polymerase activity. The lack of activity of silibinin 
in our study contrasts with a recent study showing that silybin A, silybin B, and their water-
soluble dihydrogen succinate forms found in Legalon-SIL, a commercial preparation of silibinin, 
inhibited HCV polymerase function, with IC50s in the 75 to 100 μM range.25 The water-soluble 
versions of silybin A and silybin B found in Legalon-SIL contain two succinate moieties that 
increase the molecular weight of the compound by over 244 atomic mass units, from 482 to 726. 
Thus, the water-soluble molecules are quite different chemically from the natural compounds, 
which are insoluble in water, and as a result the metabolism and biological effects of the 
compounds may differ. However, in our study, silymarin did not inhibit HCV RNA and protein 
expression in multiple independent replicon cell lines that did not produce infectious progeny 
viruses, in agreement with a recent study showing that silymarin did not inhibit HCV NS5A 
protein or RNA expression in a subgenomic replicon cell line.36 The data suggest that blockade 
of polymerase activity is not a major antiviral mechanism, at least in the HCVcc system. Instead, 
we provided evidence to suggest that inhibition of virus entry and virus transmission contribute 
to the antiviral effects of silymarin. 
 
Indeed, silymarin blocked the entry of three different enveloped pseudoviruses and also potently 
inhibited the fusion of liposome membranes. Silymarin flavonolignans belong to the family of 
phytoestrogens and are composed of a phenylbenzopyrone structure.4 The structures of these 
molecules are relatively hydrophobic, so it is possible that silymarin may act by incorporating 
into lipid membranes of both viruses and target cells, or at least may display partition into lipid 
bilayers, similar to other plant flavonoids.37 This would lead to the stabilization of membranes by 
silymarin, which would in turn become less prone to fusion. This behavior is reminiscent of 
arbidol, a broad-spectrum antiviral inhibiting HCV entry, membrane fusion, and replication.24 
This hypothesis is further corroborated by our observations that silymarin blocks cell entry of 
pseudotyped particles of other enveloped viruses such as VSVpp and MLVpp. Future studies 
will focus on further dissecting these mechanisms. 
 
We also showed that silymarin inhibits MTP activity, apoB secretion, and production of 
infectious virus particles. In support of this argument and in agreement with the results obtained 
in the current report, the flavonoid taxifolin, which is present in silymarin, has been shown to 
block MTP activity and apoB secretion.38 Silymarin has also been shown to alter lipid profiles,39 
so it is possible that the botanical may block virus transmission by targeting multiple components 
of lipid metabolism. 
 
Silymarin does many things to cells, including modulation of signal transduction,40 the redox 
state,41 T-cell function,6, 31 and nuclear factor kappa B.42 These studies suggest that direct effects 
of silymarin on cell functions are responsible for the prevention of liver disease in many animal 
models.33-35 We therefore hypothesize that silymarin's blockade of virus entry and transmission 
occurs by targeting the host cell. Studies are in progress to identify the cellular target(s) of 
silymarin that may explain the many activities elicited by this botanical. 
 
Our demonstration of anti-HCV actions of silymarin6 was initially at odds with clinical studies 
that found no effect of silymarin on HCV replication in vivo.43 However, daily intravenous 
administration of a soluble form of silibinin inhibits HCV viral loads by three to four logs in 1 to 
2 weeks in previous IFN nonresponder patients.7 This important study illustrates the clear 
differences in outcome based on route of administration and the type of silymarin-derived 
preparation being tested. Further clinical and in vitro studies are required to evaluate silymarin's 
hepatoprotective effects, metabolism, and bioavailability. Moreover, because it is now clear that 
patients with chronic hepatitis C self-prescribe botanicals, especially silymarin,3 regardless of 
whether they receive standard of care therapy with pegylated IFN plus ribavirin, it will be 
important to design clinical trials that evaluate the effects and interactions of silymarin, given 
orally and intravenously, either by itself or with antivirals for HCV, including new specifically 
targeted antiviral therapy for HCV therapies, on reduction of viral load and improvement in liver 
function or prevention of liver disease. Because of its multiple actions on cells and hypothesized 
modulation of cellular targets, silymarin and silymarin-derived compounds also may prove 
relevant for liver diseases of nonviral origin. 
 
ABBREVIATIONS 
apoB, apolipoprotein B; DMSO, dimethylsulfoxide; ELISA, enzyme-linked immunosorbent 
assay; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; HCV, hepatitis C virus; HCVcc, 
hepatitis C virus cell culture; HCVpp, hepatitis C virus pseudoparticle; IC50, half maximal 
inhibitory concentration; IFN, interferon; JFH-1, Japanese Fulminant Hepatitis; MTP: 
microsomal triglyceride transfer protein; NS5B: nonstructural 5B; R18, octadecyl rhodamine B 
chloride; RdRp: RNA dependent RNA polymerase; SM, silymarin. 
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